Generally speaking, neutralizing antibody (NAb) is an antibody that able to protect the host cell from pathogens by either neutralizing or inhibiting its biological effect. This is achieved by prohibiting interactions between the viral envelope to its host cell receptor or obstructing the release of the viral genome. Studies on NAbs provide a better understanding of humoral immune responses, as well as help researchers to gain insights into the future development of immunotherapeutic.
Creative Biolabs has developed a wide variety of neutralizing antibodies that able to recognize different virus targets and formats. We can provide low endotoxin versions for researchers who want to perform in vivo assay.
Antibodies neutralize viruses by various mechanisms:
Fig.1 Modes of viral neutralization[1].
Fig.2 Blockade of checkpoint inhibitors or moleculesFor decades, in immunotherapy areas, the development of checkpoint blocking antibodies, such as targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1), have demonstrated significant promise in the treatment of malignancies.
Creative Biolabs values the studies on immune checkpoints and has already developed various neutralizing antibodies that target popular checkpoints, including PD-1, CTLA-4, LAG3, TIGIT.
What is more, Creative Biolabs offers a range of blocking antibodies that target popular surface antigens, not only including the common antigens for hematological malignancy such as CD19, CD22, CD38, BCMA, and CS1 but also for solid tumor targets like ERBB2, GD2, MUC1, etc.
For further details, please do not hesitate to contact us and see how we can help you achieve your research goal.
References
